We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Blue Water Vaccines Inc (BWV) USD0.00001

Sell:$2.27 Buy:$2.29 Change: $0.12 (5.59%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.12 (5.59%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.12 (5.59%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Blue Water Vaccines, Inc. is a biotechnology company. It is focused on the research and development of transformational vaccines to prevent infectious diseases worldwide. Its vaccine platform has molecular properties that enables delivery of various antigens, which can be utilized to develop singular or multi-targeted vaccines. Its lead influenza (flu) vaccine program uses technology to identify specific epitopes, or proteins, with cross-reactive properties that enables the development of a universal flu vaccine. It is focused on developing novel vaccines that induce durable and long-term immunity. It is also utilizing its platform to develop a vaccine for the prevention of gastroenteritis cause by both norovirus and rotavirus. Its vaccine candidates include BWV-101 and BWV-102, an influenza vaccine program; BWV-201, which is a streptococcus pneumoniae (S. pneumoniae) vaccine program; BWV-301, a norovirus-rotavirus vaccine program, and BWV-302, a norovirus-malaria vaccine program.

Contact details

2041 Courtland Avenue
United States
+1 (646) 3030737

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$25.02 million
Shares in issue:
11.05 million
United States
US dollar

Key personnel

  • Joseph Hernandez
    Executive Chairman of the Board, Chief Executive Officer
  • Jon Garfield
    Chief Financial Officer
  • Erin Henderson
    Chief Business Officer and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.